Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly

被引:131
作者
Stomrud, Erik [1 ]
Hansson, Oskar
Blennow, Kaj
Minthon, Lennart
Londos, Elisabet
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Clin Memory Res Unit, SE-20502 Malmo, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden
关键词
Alzheimer disease; early diagnosis; dementia; mild cognitive impairment; cerebrospinal fluid biomarker; Tau protein; beta-amyloid; 42;
D O I
10.1159/000105017
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples. Methods: In this study, 57 controls were tested for CSF biomarkers at baseline and then cognitively followed over 3 years. Results: Low levels of baseline beta-amyloid 1 - 42 (A beta 42) were associated with development of subjective memory impairment affecting quality of life (memQoL), with a worse Mini Mental Status Examination score and with inability to live in regular housing at follow-up ( p < 0.05). The combination of baseline A beta 42 and phosphorylated tau (P-tau) was found to predict development of pathological memQoL with a sensitivity of 71.4% and a specificity of 75.7 (< 0.01). Conclusion: Low A beta 42 and combined A beta 42 and P-tau predicted subjective cognitive decline in healthy individuals. In summary, this study shows that already in the clinically normal population Alzheimer-disease-related biological signs might be detectable. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 37 条
  • [1] Almkvist O, 1999, EUR ARCH PSY CLIN N, V249, P3
  • [2] CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
    Andreasen, N
    Blennow, K
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2005, 107 (03) : 165 - 173
  • [3] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
    Andreasen, N
    Minthon, L
    Davidsson, P
    Vanmechelen, E
    Vanderstichele, H
    Winblad, B
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
  • [4] CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Bibl, M
    Mollenhauer, B
    Esselmann, H
    Lewczuk, P
    Klafki, HW
    Sparbier, K
    Smirnov, A
    Cepek, L
    Trenkwalder, C
    Rüther, E
    Kornhuber, J
    Otto, M
    Wiltfang, J
    [J]. BRAIN, 2006, 129 : 1177 - 1187
  • [5] Alzheimer's disease
    Blennow, Kaj
    de Leon, Mony J.
    Zetterberg, Henrik
    [J]. LANCET, 2006, 368 (9533) : 387 - 403
  • [6] Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment
    de Leon, MJ
    DeSanti, S
    Zinkowski, R
    Mehta, PD
    Pratico, D
    Segal, S
    Rusinek, H
    Li, J
    Tsui, W
    Saint Louis, LA
    Clark, CM
    Tarshish, C
    Li, Y
    Lair, L
    Javier, E
    Rich, K
    Lesbre, P
    Mosconi, L
    Reisberg, B
    Sadowski, M
    DeBernadis, JF
    Kerkman, DJ
    Harnpel, H
    Wahlund, LO
    Davies, P
    [J]. NEUROBIOLOGY OF AGING, 2006, 27 (03) : 394 - 401
  • [7] DORN H F, 1955, J Chronic Dis, V1, P638, DOI 10.1016/0021-9681(55)90221-6
  • [8] Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults
    Fagan, Anne M.
    Roe, Catherine M.
    Xiong, Chengjie
    Mintun, Mark A.
    Morris, John C.
    Holtzman, David M.
    [J]. ARCHIVES OF NEUROLOGY, 2007, 64 (03) : 343 - 349
  • [9] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN
    FOLSTEIN, MF
    FOLSTEIN, SE
    MCHUGH, PR
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) : 189 - 198
  • [10] Fratiglioni L, 2000, NEUROLOGY, V54, pS10